Log in

NASDAQ:HTBXHeat Biologics Stock Price, Forecast & News

$0.84
-0.02 (-2.31 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.83
Now: $0.84
$0.89
50-Day Range
$0.60
MA: $0.83
$1.11
52-Week Range
$0.20
Now: $0.84
$1.25
Volume5.02 million shs
Average Volume9.05 million shs
Market Capitalization$71.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.17
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.
Read More
Heat Biologics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 million
Book Value$0.39 per share

Profitability

Net Income$-20,020,000.00
Net Margins-633.58%

Miscellaneous

Employees30
Market Cap$71.54 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

How has Heat Biologics' stock been impacted by COVID-19 (Coronavirus)?

Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HTBX stock has increased by 20.7% and is now trading at $0.8449. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Heat Biologics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Heat Biologics.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Heat Biologics.

How were Heat Biologics' earnings last quarter?

Heat Biologics Inc (NASDAQ:HTBX) released its earnings results on Friday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter. The biopharmaceutical company earned $0.90 million during the quarter. Heat Biologics had a negative net margin of 633.58% and a negative return on equity of 101.83%. View Heat Biologics' earnings history.

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Shares of Heat Biologics reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for HTBX?

2 equities research analysts have issued 1 year price targets for Heat Biologics' shares. Their forecasts range from $2.00 to $8.00. On average, they expect Heat Biologics' share price to reach $5.00 in the next year. This suggests a possible upside of 491.8% from the stock's current price. View analysts' price targets for Heat Biologics.

Has Heat Biologics been receiving favorable news coverage?

Headlines about HTBX stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Heat Biologics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Heat Biologics.

Who are some of Heat Biologics' key competitors?

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Opko Health (OPK), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Alibaba Group (BABA), NVIDIA (NVDA), Gilead Sciences (GILD), Vaxart (VXRT), Johnson & Johnson (JNJ) and Advanced Micro Devices (AMD).

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the following people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
  • Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
  • Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $0.84.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $71.54 million and generates $3.05 million in revenue each year. Heat Biologics employs 30 workers across the globe.

What is Heat Biologics' official website?

The official website for Heat Biologics is www.heatbio.com.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.